Managing CNS and Systemic Responses In R/R MM: Monitoring and Sequencing Strategies with Elranatamab and Cilta-Cel

EP: 1.Meet a 76-Year-Old Patient With Late-Line R/R MM, Unsuitable For CAR T Therapy

EP: 2.Role of Step-Up Dosing

EP: 3.Dosing Frequency, and Adverse Event Management With Bispecific Therapy

EP: 4.Strategies For Management of Infections

EP: 5.Optimizing Treatment Goals and Supportive Care For Relapsed/Refractory Multiple Myeloma in Older Patients

EP: 6.Meet a 55-Year-Old Who Was Refractory to or Relapsed on BCMA CAR T Therapy

EP: 7.Patient Tolerability of Talquetamab and Use of IVIG

EP: 8.Strategizing Talquetamab Use In Relapsed/Refractory Multiple Myeloma: Balancing Efficacy, Infection Control, and Next-Line Therapy

EP: 9.Meet our 61-Year-Old Patient With Late-Line R/R on a BCMA-Targeting Bispecific

EP: 10.Dosing Strategies in Different Targets Bispecifics

Now Viewing

EP: 11.Managing CNS and Systemic Responses In R/R MM: Monitoring and Sequencing Strategies with Elranatamab and Cilta-Cel

EP: 12.Handling an Intricate Case of R/R MM With BCMA/GPRC5D Bispecific Antibodies

Video content above is prompted by the following:

• What would your follow-up monitoring plan look like to assess both CNS and systemic responses to elranatamab?
• What treatment sequencing strategy would you use if disease progression occurs, particularly balancing the need for CNS efficacy and minimizing systemic toxicity?
• Given the response he has made on elranatamab, how would you counsel him on the potential benefits and risks of continuing vs sequencing to cilta-cel?